Send us Feedback

Incyte (INCY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

INCY » Topics » HIV Opportunity

This excerpt taken from the INCY 8-K filed Nov 2, 2006.

HIV Opportunity

 

CCR5 Antagonist

We have completed the single- and multiple-dose-escalation Phase I trials in healthy volunteers for our lead oral CCR5 antagonist, INCB9471, and initiated a 14-day Phase IIa trial evaluating INCB9471 as monotherapy in treatment-naïve HIV-infected patients and treatment-experienced HIV-infected patients not currently on HIV therapy.  Top-line safety and efficacy results from this trial are expected early in 2007. 

 

In parallel with the development of INCB9471, we plan to file an IND for a second CCR5 compound, INCB15050, and begin Phase I testing in healthy volunteers by year-end.

 

This excerpt taken from the INCY 8-K filed Jul 27, 2006.

HIV Opportunity

CCR5 Antagonist
In May, we initiated Phase I testing in healthy volunteers for our oral CCR5 antagonist compound, INCB9471, and expect to initiate a Phase IIa trial in treatment-experienced HIV patients in October of this year.  In parallel with the development of INCB9471, we are moving a second CCR5 compound, INCB15050, forward.  This compound is expected to complete IND-enabling toxicology studies later this year.

EXCERPTS ON THIS PAGE:

8-K
Nov 2, 2006
8-K
Jul 27, 2006

RELATED TOPICS for INCY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki